

Davood Khalili

Date Prepared: Aug 2019
Office Address: Department of Biostatistics and Epidemiology, Research Institute for Endocrine Sciences, No. 23, Arabi st, Velenjak, Tehran, Iran
Cell Phone: +98 9128148865
Academic Email: dkhalili@endocrine.ac.ir ; dkhalili@hsph.harvard.edu

Education

Official degrees:

2012	Medical Specialty (MD, PhD)	Epidemiology	Shahid Beheshti University of Medical Sciences, Tehran
2008	Master (MPH)	Public Health	Shahid Beheshti University of Medical Sciences, Tehran
1998	MD	Medicine	Urmia University of Medical Sciences, Urmia, Iran

Other advanced training

2019	Clinical Genomics	31st Course jointly organized by ESGM, ESHG, and CEUB
2016	Iran Diabetes Advancement in Research	The American Association of Continuing Medical Education, Sanofi Group Middle East
2011	Epidemiology and Biostatistics	Erasmus Summer Program, Erasmus MC University, Rotterdam, The Netherlands
2011	Recent Developments in Epidemiologic Research	International Epidemiological Association, Edinburgh, Scotland

PhD Thesis:

Validation, Recalibration and Clinical Usefulness of the Framingham Risk Function for Cardiovascular Diseases in an Iranian Population.

Academic Appointments

Faculty member:

2019 -	Associate Professor	Prevention of Metabolic Disorders Research Center	Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran
2013 -2018	Assistant Professor	Prevention of Metabolic Disorders Research Center	Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran

Other Affiliated Institutions:

2017 -	Lown Scholar	Department of Global Health and Population	Harvard T.H. Chan School of Public Health, Boston, MA
2017	Visiting Scholar	Department of Biomedical Data Sciences	Leiden University Medical Center (LUMC), The Netherlands
2016 -	Adjunct Professor	Department of Epidemiology	School of Public Health, Iran University of Medical Sciences

Other Professional Positions:

2016-2017, 2019	Consultant	World Health Organization	By project
2016-2018	International Advisory board	The Middle East, Mediterranean and Africa Cardiovascular Clinical Trialists (CVCT, MEMA)	Annual meetings
2016-2018	Board member	The Scientific Association for Public Health in Iran (SAPHIR)	Monthly meetings
2013 -	Advisory board	Clinical Trial Center, Tehran University of Medical Sciences	Annual meetings & monthly journal clubs

Major Administrative Leadership Positions

Local

2015-	Director	Department of Biostatistics and Epidemiology, Research Institute for Endocrine Sciences, Tehran
2012-2015	Research manager	Research Deputy, Research Institute for Endocrine Sciences, Tehran

National

2014-	Secretary-General	Iran Cohort Consortium
-------	-------------------	------------------------

Committee Service:

Local

2012 -	Member, Institutional Review Board committee	Research Institute for Endocrine Sciences
--------	---	---

National

2016 -	Member, Council of education and research	Iran Cohort Consortium
--------	---	------------------------

Clinical Practice:

1999-2001	General Practitioner	Emergency unite, Manjil Hospital, Guilan province, Iran
2001-2007	General Practitioner	Urban & rural health centers, Guilan province, Iran

During these years I had the opportunity to acquire firsthand experience of primary and secondary care in a variety of urban and rural settings which helped me to identify the gaps and shaped and informed my future research career.

Editorial Activities

- **Ad hoc Reviewer:**

- The Lancet
- The Lancet Global Health
- Annals of Internal Medicine
- PLOS Medicine
- American Journal of Cardiology
- Journal of Clinical Epidemiology
- PLOS ONE
- BMC journals
- Preventive Medicine
- Lipids in Health and Disease
- International Journal of Information Technology & Decision Making
- Archives of Iranian Medicine
- Asia Pacific Journal of Cancer Prevention
- Journal of Research in Health Sciences
- Journal of Diabetes & Metabolic Disorders
- The Journal of Tehran Heart Center
- Iranian Journal of Epidemiology

- **Editorial Roles:**

2014 - Associate editor

International Journal of Endocrinology and Metabolism

2014 - Associate editor

Iranian Journal of Endocrinology and Metabolism

Other Review Activities

National research Grant / Audit

2019 -	WHO STEPS survey committee	Ad hoc reviewer, National Institute of Health Research
2017 -	Non-Communicable Diseases committee	Ad hoc Member, National Institute for Medical Research Development (NIMAD)

Honors and Prizes:

2019	A letter of appreciation	Ministry of Health and Medical Education	For an elaborate review and evaluation of some research centers
2017	Honor researcher	Shahid Beheshti University of Medical Sciences, Tehran	Ranked first among assistant professors in the University
2015	Excellent Scientist	Vice-Presidency for Science and Technology, Iran	Among top 100 researchers
2011	Honor researcher	Shahid Beheshti University of Medical Sciences, Tehran	Ranked first among non-faculty members in the University
2009	Honor PhD student	Shahid Beheshti University of Medical Sciences, Tehran	Ranked first among PhD students in the school of public health
2008	Honor PhD student	Shahid Beheshti University of Medical Sciences, Tehran	Ranked first among PhD students in the school of public health
2009	A letter of appreciation	Ministry of Health and Medical Education	For contribution in the construction of Iranian Registry of Clinical Trials as a primary registry of WHO
2000	Honor researcher	Guilan University of Medical Sciences, Rasht, Iran	Among the best researchers in the University

Funded Projects

During the past 3 years

- 2017 Updating diabetes risk scoring for the Iranian population, WHO, PI
- 2017 Situation analysis to Implement adapted tools in the demonstration site of HEART initiatives in Iran, WHO, PI
- 2017 Long-term effectiveness of a community-based field trial targeting lifestyle and education interventions on the incidence of type 2 diabetes and metabolic syndrome. Research Institute for Endocrine Sciences, PI
- 2016 Developing Iran Cohort Consortium, PI
- 2016 Providing metadata for Tehran Lipid and Glucose Study. Research Institute for Endocrine Sciences, PI
- 2016 Updating CVD risk scoring for implementation in primary health care based on updated CVD risk score, WHO recommendations and country circumstances, WHO, PI
- 2015 Comprehensive Monitoring and Evaluation of Screening Program for Congenital Hypothyroidism, Research Institute for Endocrine Sciences, Co-PI

Current

- 2019 To develop a pilot plan for IraPEN program and a no-lab prediction model for assessment of NCDs risk factors, WHO, PI, \$25000
- 2018 Cost-effectiveness of the risk-based prevention of cardiovascular diseases in primary health care: National Institute for Medical Research Development (NIMAD), Iran, PI, 756,000,000 Rials by NIMAD and \$10,118 by Harvard T.H. Chan School of Public Health
- 2018 To study the trend of risk for cardiovascular diseases during the past decade and estimate the incidence of these diseases during the next decade in Iran, National Institute for Medical Research Development (NIMAD), PI, 275,000,000 Rials
- 2018 Validation of the American Diabetes Association (ADA) diabetes screening score in an Iranian population: Its diagnostic and prognostic power, National Institute for Medical Research Development (NIMAD), PI, 275,000,000 Rials

Other funded projects and all unfunded ones, resulted in original articles, are presented as publications in peer-reviewed journals.

Teaching and Training

Teaching of Students in Courses:

2016-	Clinical prediction models, for PhD students in epidemiology	Department of Epidemiology, Iran University of Medical Sciences, Tehran
2017-	Advanced research methodology, for PhD by research students and physician-scientists	Shahid Beheshti University of Medical Sciences, Tehran

Formal Teaching of Residents and Fellows:

2015-	Research Methodology for residents and fellows	Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran
-------	--	---

Research Supervision of Students and Fellows:

2019 -	Determination of trajectory of metabolic risk factors and biomarkers in patients with prediabetes prior to the development of diabetes	Co-supervisor, Endocrinology Fellow, Research Institute for Endocrine Sciences, Tehran
2019 -	The association of insulin resistance and beta-cell dysfunction with prediabetes and determination of a cut-off point for HOMA-IR and HOMA-B to predict prediabetes	Co-supervisor, Endocrinology Fellow, Research Institute for Endocrine Sciences, Tehran
2019 -	Application of dynamic prediction models for three-year incident dysglycemia and type 2 diabetes using Joint modeling of longitudinal and time-to-event data in population-based cohorts	Co-supervisor, PhD student, Research Institute for Endocrine Sciences, Tehran
2019 -	The risk threshold for initiating cardiovascular preventive therapy based on the evidence-based decision-making model	Co-supervisor, PhD students, Department of Epidemiology, Iran University of Medical Sciences, Tehran
2018 -	A cost-effectiveness analysis of risk-based intervention for the prevention of cardiovascular disease in IraPEN: A pilot study in Iran	Co-supervisor, MS student, University of Oslo, Norway
2017 -	The net benefit of using Globorisk risk score to identify high-risk individuals for cardiovascular diseases	Co-supervisor, PhD students, Department of Epidemiology, Iran University of Medical Sciences, Tehran
2016 -	Effectiveness of lifestyle intervention programs for type 2 diabetes prevention in resource-constrained settings	Co-supervisor, PhD student, Non-Communicable Disease Control Unit (NCDU), University of Melbourne, Australia
2016-2018	Comprehensive Monitoring and Evaluation of Screening Program for Congenital Hypothyroidism	Co-supervisor, PhD student, Research Institute for Endocrine Sciences, Tehran

2016-2018	Determining a national risk function to predict cardiovascular diseases mortality using the pooled data of population-based cohorts and surveys of Iran	Co-supervisor, PhD student, Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran
2015-2017	Assessment of lifestyle pattern among Iranian population using Self-organizing map and Latent class cluster analysis methods and its association with blood pressure	Co-supervisor, PhD student, Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran
2015-2016	The latent classes of metabolic syndrome components and the effect of the intervention program on changing these classes over time	Supervisor, MS student, Department of Epidemiology, Shahid Beheshti University of Medical Sciences, Tehran

Invited Presentations

Local & National

2012-2018 At least 10 local & national invited talks regarding cohort studies, prediction models and cardiometabolic risk factors in Iran

Regional

2016 The situation of cardiovascular diseases in Africa and Middle East. Middle East, Mediterranean and Africa Cardiovascular Clinical Trialists (CVCT, MEMA) Forum. Abu Dhabi, United Arab Emirates

2017 WHO Package of Essential Noncommunicable (PEN) disease interventions for primary health care. Middle East, Mediterranean and Africa Cardiovascular Clinical Trialists (CVCT, MEMA) Forum. Cairo, Egypt (However, I was unable to attend because of visa)

Publications in Peer-Reviewed Journals

1. Azizi F, Hadaegh F, Hosseinpanah F, Mirmiran P, Amouzegar A, Abdi H, Asghari G, Parizadeh D, Montazeri SA, Lotfaliany M, Takyar F, **Khalili D***. *Metabolic health in the Middle East and north Africa. Lancet Diabetes Endocrinol.* 2019 August 14, Published Online
2. Danaei G, Farzadfar F, Kelishadi R, Rashidian A, Rouhani OM, Ahmadnia S, Ahmadvand A, Arabi M, Ardalan A, Arhami M, Azizi MH, Bahadori M, Baumgartner J, Beheshtian A, Djalalinia S, Doshmangir L, Haghdoost AA, Haghshenas R, Hosseinpoor AR, Islami F, Kamangar F, **Khalili D**, Madani M, Masoumi-Asl H, Mazyaki A, Mirchi A, Moradi E, Nayernouri T, Niemeier D, Omidvari AH, Peykari N, Pishgar F, Qorbani M, Rahimi K, Rahimi-Movaghar A, Tehrani FR, Rezaei N, Shahrzad S, Takian A, Tootee A, Ezzati M, Jamshidi HR, Larijani B, Majdzadeh R, Malekzadeh R. *Iran in transition. Lancet.* 2019 May 11;393(10184):1984-2005.
3. NCD Risk Factor Collaboration (NCD-RisC). Rising rural body-mass index is the main driver of the global obesity epidemic in adults. *Nature.* 2019 May;569(7755):260-264.
4. Khajavi A, **Khalili D**, Azizi F, Hadaegh F. *Impact of temperature and air pollution on cardiovascular disease and death in Iran: A 15-year follow-up of Tehran Lipid and Glucose Study. Sci Total*

5. Lotfaliany M, Hadaegh F, Asgari S, Mansournia MA, Azizi F, Oldenburg B, **Khalili D***. *Non-invasive Risk Prediction Models in Identifying Undiagnosed Type 2 Diabetes or Predicting Future Incident Cases in the Iranian Population.* **Arch Iran Med.** 2019 Mar 1;22(3):116-124.
6. **Khalili D**, Asgari S, Lotfaliany M, Zafari N, Hadaegh F, Momenan AA, Nowroozpoor A, Hosseini-Esfahani F, Mirmiran P, Amiri P, Azizi F. *Long-Term Effectiveness of a Lifestyle Intervention: A Pragmatic Community Trial to Prevent Metabolic Syndrome.* **Am J Prev Med.** 2019 Mar;56(3):437-446.
7. Mehran L, **Khalili D**, Yarahmadi S, Delshad H, Mehrabi Y, Amouzegar A, Ajang N, Azizi F. *Evaluation of the congenital hypothyroidism screening programme in Iran: a 3-year retrospective cohort study.* **Arch Dis Child Fetal Neonatal Ed.** 2019 Mar;104(2):F176-F181.
8. Ahanchi NS, Hadaegh F, Alipour A, Ghanbarian A, Azizi F, **Khalili D***. *Application of Latent Class Analysis to Identify Metabolic Syndrome Components Patterns in adults: Tehran Lipid and Glucose study.* **Sci Rep.** 2019 Feb 7;9(1):1572.
9. Amiri P, Vahedi-Notash G, Naseri P, **Khalili D**, Hashemi Nazari SS, Mehrabi Y, Mahdavi Hazaveh AR, Azizi F, Hadaegh F. *National trends of pre-hypertension and hypertension among Iranian adolescents across urban and rural areas (2007-2011).* **Biol Sex Differ.** 2019 Mar 29;10(1):15.
10. Farahmand M, Ramezani Tehrani F, **Khalili D**, Cheraghi L, Bahri Khomami M, Azizi F. *Association between duration of endogenous estrogen exposure and cardiovascular outcomes: A population - based cohort study.* **Life Sci.** 2019 Mar 15;221:335-340.
11. **Khalili D**, Azizi F, Asgari S, Zadeh-Vakili A, Momenan AA, Ghanbarian A, Eskandari F, Sheikholeslami F, Hadaegh F. *Outcomes of a Longitudinal Population-based Cohort Study and Pragmatic Community Trial: Findings from 20 Years of the Tehran Lipid and Glucose Study.* **Int J Endocrinol Metab.** 2018 Oct; 16(4 Suppl):e84748.
12. Akbarpour S, **Khalili D**, Zeraati H, Mansournia MA, Ramezankhanim A, Fotouhi A. *Lifestyle patterns in the Iranian population: Self-organizing map application.* **Caspian J Intern Med.** 2018 Summer;9(3):268-275.
13. Ramezankhani A, Harati H, Bozorgmanesh M, Tohidi M, **Khalili D**, Azizi F, Hadaegh F. *Diabetes Mellitus: Findings from 20 Years of the Tehran Lipid and Glucose Study.* **Int J Endocrinol Metab.** 2018 Oct 16;16(4 Suppl):e84784.
14. Lotfaliany M, Akbarpour S, Zafari N, Mansournia MA, Asgari S, Azizi F, Hadaegh F, **Khalili D***. *World Bank Income Group, Health Expenditure or Cardiometabolic Risk Factors? A Further Explanation of the Wide Gap in Cardiometabolic Mortality Between Worldwide Countries: An Ecological Study.* **Int J Endocrinol Metab.** 2018 Jul; 16(3):e59946.
15. Fahimfar N, **Khalili D**, Sepanlou SG, Malekzadeh R, Azizi F, Mansournia MA, Roohafza H, Emamian MH, Hadaegh F, Poustchi H, Mansourian M, Hashemi H, Sharafkhah M, Pourshams A, Farzadfar F, Steyerberg EW, Fotouhi A. *Cardiovascular mortality in a Western Asian country: results from the Iran Cohort Consortium.* **BMJ Open.** 2018 Jul 5;8(7):e020303.
16. Zafari N, Lotfaliany M, Mansournia MA, **Khalili D**, Azizi F, Hadaegh F. *Optimal cut-points of different anthropometric indices and their joint effect in prediction of type 2 diabetes: results of a cohort study.* **BMC Public Health.** 2018 Jun 5;18(1):691.

17. Bakhtiyari M, Schmidt N, Hadaegh F, **Khalili D**, Mansournia N, Asgari S, Mansournia MA. *Direct and indirect effects of central and general adiposity on cardiovascular diseases: The Tehran Lipid and Glucose Study*. **Eur J Prev Cardiol**. 2018 Jul;25(11):1170-1181.
18. Akbarpour S, **Khalili D**, Zeraati H, Mansournia MA, Ramezankhani A, Fotouhi A. *Healthy lifestyle behaviors and control of hypertension among adult hypertensive patients*. **Sci Rep**. 2018 May 31;8(1):8508.
19. Rabani S, Sardarinia M, Akbarpour S, Azizi F, **Khalili D**, Hadaegh F. *12-year trends in cardiovascular risk factors (2002-2005 through 2011-2014) in patients with cardiovascular diseases: Tehran lipid and glucose study*. **PLoS One**. 2018 May 16;13(5):e0195543.
20. Amiri P, Jalali-Farahani S, Akbar HM, Cheraghi L, **Khalili D**, Momenan A, Mirmiran P, Ghanbarian A, Hedayati M, Hosseini-Esfahani F, Azizi F. *The Effects of a Community-Based Lifestyle Intervention on Metabolic Syndrome and Its Components in Adolescents: Findings of a Decade Follow-Up*. **Metab Syndr Relat Disord**. 2018 Jun;16(5):215-223.
21. Asgari S, Abdi H, Hezaveh AM, Moghisi A, Etemad K, Beni HR, **Khalili D***. *The Burden of Statin Therapy based on ACC/AHA and NCEP ATP-III Guidelines: An Iranian Survey of Non-Communicable Diseases Risk Factors*. **Sci Rep**. 2018 Mar 21;8(1):4928
22. Mehran L, **Khalili D**, Yarahmadi S, Delshad H, Mehrabi Y, Amouzegar A, Ajang N, Azizi F. *Evaluation of the congenital hypothyroidism screening programme in Iran: a 3-year retrospective cohort study*. **Arch Dis Child Fetal Neonatal Ed**. 2018 Mar 14. pii: fetalneonatal-2017-313720.
23. Kabootari M, Asgari S, Mansournia MA, **Khalili D**, Valizadeh M, Azizi F, Hadaegh F. *Different Weight Histories and Risk of Incident Coronary Heart Disease and Stroke: Tehran Lipid and Glucose Study*. **J Am Heart Assoc**. 2018 Feb 10;7(4). pii: e006924.
24. Kazemi Jaliseh H, Ramezani Tehrani F, Behboudi-Gandevani S, Hosseinpanah F, **Khalili D**, Cheraghi L, Azizi F. *Polycystic ovary syndrome is a risk factor for diabetes and prediabetes in middle-aged but not elderly women: a long-term population-based follow-up study*. **Fertil Steril**. 2017 Dec;108(6):1078-1084.
25. Mehran L, **Khalili D**, Yarahmadi S, Amouzegar A, Mojarrad M, Ajang N, Azizi F. *Worldwide Recall Rate in Newborn Screening Programs for Congenital Hypothyroidism*. **Int J Endocrinol Metab**. 2017 Jun 25;15(3):e55451.
26. Gilani N, Kazemnejad A, Zayeri F, Hadaegh F, Azizi F, **Khalili D**. *Anthropometric Indices as Predictors of Coronary Heart Disease Risk: Joint Modeling of Longitudinal Measurements and Time to Event*. **Iran J Public Health**. 2017 Nov;46(11):1546-1554.
27. Amiri P, Jalali-Farahani S, Masihay Akbar H, Cheraghi L, **Khalili D**, Momenan A, Mirmiran P, Ghanbarian A, Hedayati M, Hosseini-Esfahani F, Azizi F. *The Effects of a Community-Based Lifestyle Intervention on Metabolic Syndrome and Its Components in Adolescents: Findings of a Decade Follow-Up*. **Metab Syndr Relat Disord**. 2018 Apr. [Epub ahead of print]
28. Saeed Kalantari, **Davood Khalili ***, Samaneh Asgari, Noushin Fahimfar, Farzad Hadaegh, Maryam Tohidi and Fereidoun Azizi. *Predictors of early adulthood hypertension during adolescence: a population-based cohort study*. **BMC Public Health** 2017 17:915
29. Mehran L, Yarahmadi S, **Khalili D**, Nazeri P, Delshad H, Abdollahi Z, Azhang N, Azizi F. *The Impact of Iodine Status on the Recall Rate of the Screening Program for Congenital Hypothyroidism: Findings from Two National Studies in Iran*. **Nutrients**. 2017 Oct 30;9(11).

30. Taravatmanesh S, **Khalili D**, Khodakarim S, Asgari S, Hadaegh F, Azizi F, Sabour S. *Determining the Factors Associated with Cardiovascular Disease Recurrence: Tehran Lipid and Glucose Study*. **J Tehran Heart Cent**. 2017 Jul;12(3):107-113.
31. Kazemijaliseh H, Ramezani Tehrani F, Behboudi-Gandevani S, **Khalili D**, Hosseinpanah F, Azizi F. *A Population-Based Study of the Prevalence of Abnormal Uterine Bleeding and its Related Factors among Iranian Reproductive-Age Women: An Updated Data*. **Arch Iran Med**. 2017 Sep;20(9):558-563.
32. Amiri M, Nahidi F, **Khalili D**, Bidhendi-Yarandi R, Ramezani Tehrani F. *Comparing the Effects of Oral Contraceptives Containing Levonorgestrel With Products Containing Antiandrogenic Progestins on Clinical, Hormonal, and Metabolic Parameters and Quality of Life in Women With Polycystic Ovary Syndrome: Crossover Randomized Controlled Trial Protocol*. **JMIR Res Protoc**. 2017 Sep 29;6(9):e191.
33. Mansournia MA, Holakouie-Naieni K, Fahimfar N, Almasi-Hashiani A, Cheraghi Z, Ayubi E, Hadaegh F, Eskandari F, Azizi F, **Khalili D***. *Risk of Coronary Heart Events Based on Rose Angina Questionnaire and ECG Besides Diabetes and Other Metabolic Risk Factors: Results of a 10-Year Follow-up in Tehran Lipid and Glucose Study*. **Int J Endocrinol Metab**. 2017 Apr 24;15(2):e42713.
34. Farahmand M, Ramezani Tehrani F, **Khalili D**, Amin G, Negarandeh R. *Factors associated with the severity of premenstrual syndrome among Iranian college students*. **J Obstet Gynaecol Res**. 2017 Nov;43(11):1726-1731.
35. Ramezankhani A, Bagherzadeh-Khiabani F, **Khalili D**, Azizi F, Hadaegh F. *A new look at risk patterns related to coronary heart disease incidence using survival tree analysis: 12 Years Longitudinal Study*. **Sci Rep**. 2017 Jun 12;7(1):3237.
36. Daneshpour MS, Fallah MS, Sedaghati-Khayat B, Guity K, **Khalili D**, Hedayati M, Ebrahimi A, Hajsheikhholeslami F, Mirmiran P, Ramezani Tehrani F, Momenan AA, Ghanbarian A, Amouzegar A, Amiri P, Azizi F. *Rationale and Design of a Genetic Study on Cardiometabolic Risk Factors: Protocol for the Tehran Cardiometabolic Genetic Study (TCGS)*. **JMIR Res Protoc**. 2017 Feb 23;6(2):e28.
37. Peter Ueda, Mark Woodward, Yuan Lu, Kaveh Hajifathalian, Rihab Al-Wotayan, Carlos A Aguilar-Salinas, Alireza Ahmadvand, Fereidoun Azizi, James Benthall, Renata Cifkova, Mariachiara Di Cesare, Louise Eriksen, Farshad Farzadfar, Trevor S Ferguson, Nayu Ikeda, **Davood Khalili**, Young-Ho Khang, Vera Lanska, Luz León-Muñoz, Dianna Magliano, Paula Margozzini, Kelias P Msyamboza, Gerald N Mutungi, Kyungwon Oh, Sophal Oum, Fernando Rodríguez-Artalejo, Rosalba Rojas-Martinez, Gonzalo Valdivia, Rainford Wilks, Jonathan E Shaw, Gretchen A Stevens, Janne Tolstrup, Bin Zhou, Joshua A Salomon, Majid Ezzati, Goodarz Danaei. *Laboratory-based and office-based cardiovascular risk scores and charts for prediction of 10-year risk of fatal and non-fatal cardiovascular disease in 182 countries: a pooled analysis*. **Lancet Diabetes Endocrinol**. 2017 Mar;5(3):196-213.
38. Golozar A, **Khalili D**, Etemadi A, Poustchi, Fazeltabar, Hosseini, Kamangar F, Khoshnia M, Islami F, Hadaegh F, Brennan P, Boffetta P, Abnet CC, Dawsey SM, Azizi F, Malekzadeh R, Danaei G. *White rice intake and incidence of type-2 diabetes: analysis of two prospective cohort studies from Iran*. **BMC Public Health**. 2017, 31;17(1):133.
39. Barzin M, Motamedi MA, Serahati S, Khalaj A, Arian P, Valizadeh M, **Khalili D**, Azizi F, Hosseinpanah F. *Comparison of the Effect of Gastric Bypass and Sleeve Gastrectomy on Metabolic Syndrome and its Components in a Cohort: Tehran Obesity Treatment Study (TOTS)*. **Obes Surg**.

40. Eslami A, Mozaffary A, Derakhshan A, Azizi F, **Khalili D**, Hadaegh F. *Sex-specific incidence rates and risk factors of premature cardiovascular disease. A long term follow up of the Tehran Lipid and Glucose Study.* **Int J Cardiol.** 2017. 15;227:826-832.
41. Asgari S, Barzin M, Hosseinpanah F, Hadaegh F, Azizi F, **Khalili D***. *Obesity Paradox and Recurrent Coronary Heart Disease in a Population-Based Study: Tehran Lipid and Glucose Study.* **Int J Endocrinol Metab.** 2016 Apr 16;14(2).
42. Panahi MH, Hadaegh F, Yavari P, Kazempour-Ardebili S, Mehrabi Y, Azizi F, **Khalili D***. *A Challenging Interaction of Chronic Kidney Disease With Other Metabolic Disorders: Paradoxes in Cardiometabolic Risk Factors.* **Iran J Kidney Dis.** 2016 Sep;10(5):274-281.
43. Cheraghi Z, Mirmiran P, Mansournia MA, Moslehi N, **Khalili D**, Nedjat S. *The association between nutritional exposures and metabolic syndrome in the Tehran Lipid and Glucose Study (TLGS): a cohort study.* **Public Health.** 2016;140:163-171.
44. NCD Risk Factor Collaboration (NCD-RisC). *A century of trends in adult human height.* **Elife.** 2016 Jul 26;5.
45. Shaseb E, Tohidi M, Abbasinazari M, **Khalili D**, Talasaz AH, Omrani H, Hadaegh F. *The effect of a single dose of vitamin D on glycemic status and C-reactive protein levels in type 2 diabetic patients with ischemic heart disease: a randomized clinical trial.* **Acta Diabetol.** 2016 Aug;53(4):575-82.
46. Ghasemzadeh Z, Abdi H, Asgari S, Tohidi M, **Khalili D**, Valizadeh M, Moeini S, Eidkhani V, Azizi F, Hadaegh F. *Divergent pathway of lipid profile components for cardiovascular disease and mortality events: Results of over a decade follow-up among Iranian population.* **Nutr Metab (Lond).** 2016 Jun 24;13:43.
47. Helgadottir A, Gretarsdottir S, Thorleifsson G, Hjartarson E, Sigurdsson A, Magnusdottir A, Jonasdottir A, Kristjansson H, Sulem P, Oddsson A, Sveinbjornsson G, Steinthorsdottir V, Rafnar T, Masson G, Jonsdottir I, Olafsson I, Eyjolfsson GI, Sigurdardottir O, Daneshpour MS, **Khalili D**, Azizi F, Swinkels DW, Kiemeny L, Quyyumi AA, Levey AI, Patel RS, Hayek SS, Gudmundsdottir IJ, Thorgeirsson G, Thorsteinsdottir U, Gudbjartsson DF, Holm H, Stefansson K. *Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease.* **Nature Genetics.** 2016 Jun;48(6):634-9.
48. Ramezani Tehrani F, Montazeri SA, **Khalili D**, Cheraghi L, Broekmans FJ, Momenan AA, de Kat AC, Azizi F. *Age-specific anti-Müllerian hormone and electrocardiographic silent coronary artery disease.* **Climacteric.** 2016 Aug;19(4):344-8
49. Bagherzadeh-Khiabani F, Steyerberg EW, **Khalili D***. *THE AUTHORS REPLY to Letter to the Editor re: Bagherzadeh-Khiabani et al.* **J Clin Epidemiol.** 2016 Jul;75:131-2.
50. NCD Risk Factor Collaboration (NCD-RisC). *Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants.* **Lancet.** 2016 Apr 9;387(10027):1513-30.
51. NCD Risk Factor Collaboration (NCD-RisC). *Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants.* **Lancet.** 2016 Apr 2;387(10026):1377-96.
52. Khiabani FB, Ramezankhani A, Azizi F, Hadaegh F, Steyerberg EW, **Khalili D***. *A tutorial on variable selection for clinical prediction models: Feature selection methods in data-mining could*

improve the results. **J Clin Epidemiol.** 2016 Mar;71:76-85.

53. Hadaegh F, Derakhshan A, Mozaffary A, Hasheminia M, **Khalili D**, Azizi F. *Twelve-Year Cardiovascular and Mortality Risk in Relation to Smoking Habits in Type 2 Diabetic and Non-Diabetic Men: Tehran Lipid and Glucose Study.* **PLoS One.** 2016 Mar 1;11(3):e0149780.
54. Barzin M, Hosseinpanah, Motamedi MA, Shapoori P, Arian P, Daneshpour MA, Asghari G, Teymoornejad A, Eslamifar A, **Khalili D**, Jodeiri B, Alamdari S, Azizi F, Khalaj A. *Bariatric Surgery for Morbid Obesity: Tehran Obesity Treatment Study (TOTS) Rationale and Study Design.* **JMIR Res Protoc.** 2016 Jan 20;5(1):e8.
55. Afsharian S, Akbarpour S, Abdi H, Sheikholeslami F, Moeini AS, **Khalili D**, Momenan AA, Azizi F, Hadaegh F1. *Risk factors for cardiovascular disease and mortality events in adults with type 2 diabetes: a 10 year follow-up: Tehran lipid and glucose study.* **Diabetes Metab Res Rev.** 2016 Sep;32(6):596-606.
56. Asgari S, **Khalili D**, Mehrabi Y, Kazempour-Ardebili S, Azizi F, Hadaegh F. *Incidence and risk factors of isolated systolic and diastolic hypertension: a 10 year follow-up of the Tehran Lipids and Glucose Study.* **Blood Press.** 2016 Jun;25(3):177-83.
57. Hadaegh F, Derakhshan A, Zafari N, **Khalili D**, Mirbolouk M, Saadat N, Azizi F. *Pre-diabetes tsunami: incidence rates and risk factors of pre-diabetes and its different phenotypes over 9 years of follow-up.* **Diabet Med.** 2015 Nov 25. doi: 10.1111/dme.13034. [Epub ahead of print]
58. Masudi S, Yavari P, Mehrabi Y, Azizi F, **Khalili D***. *Underestimating the Effect of Lipids on Cardiovascular Events: Regression Dilution Bias in the Population-Based Cohort of Tehran Lipid and Glucose Study.* **Int J Endocrinol Metab.** 2015 Oct 3;13(4):e27528.
59. Hadaegh F, Hasheminia M, Abdi H, **Khalili D**, Bozorgmanesh M, Arshi B, Azizi F. *Prehypertension Tsunami: A Decade Follow-Up of an Iranian Adult Population.* **PLoS One.** 2015 Oct 6;10(10).
60. Hashemi Nazari SS, Shakiba M, **Khalili D***, Hadaegh F, Tohidi M, Azizi F. *High-density lipoprotein cholesterol, a protective or a risk factor for developing coronary heart disease? Tehran Lipid and Glucose Study.* **J Clin Lipidol.** 2015 Jul-Aug;9(4):553-8.
61. Masudi S, Yavari P, Mehrabi Y, **Khalili D**, Azizi F. *Regression dilution bias in blood pressure and body mass index in a longitudinal population-based cohort study.* **J Res Health Sci.** 2015 Spring;15(2):77-82.
62. Kazemijalish H, Ramezani Tehrani F, Behboudi-Gandevani S, Hosseinpanah F, **Khalili D**, Azizi F. *The Prevalence and Causes of Primary Infertility in Iran: A Population-Based Study.* **Glob J Health Sci.** 2015 Apr 19;7(6):45001.
63. Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-Salinas CA, Azizi F, Cifkova R, Di Cesare M, Eriksen L, Farzadfar F, Ikeda N, **Khalili D**, Khang YH, Lanska V, León-Muñoz L, Magliano D, Msyamboza KP, Oh K, Rodríguez-Artalejo F, Rojas-Martinez R, Shaw JE, Stevens GA, Tolstrup J, Zhou B, Salomon JA, Ezzati M, Danaei G. *A novel risk score to predict cardiovascular disease risk in national populations (Gborisk): a pooled analysis of prospective cohorts and health examination surveys.* **Lancet Diabetes Endocrinol.** 2015 May;3(5):339-55.
64. Azimi SS, **Khalili D***, Hadaegh F, Yavari P, Mehrabi Y, Azizi F. *Calculating population attributable fraction for cardiovascular risk factors using different methods in a population based cohort study.* **J Res Health Sci.** 2015 Winter;15(1):22-7.
65. Khalili M, Vasei M, **Khalili D**, Alimoghaddam K, Sadeghizadeh M, Mowla SJ. *Downregulation of the*

Genes Involved in Reprogramming (SOX2, c-MYC, miR-302, miR-145, and P21) in Gastric Adenocarcinoma. **J Gastrointest Cancer.** 2015 Sep;46(3):251-8.

66. **Khalili D**, Asgari S, Hadaegh F, Steyerberg EW, Rahimi K, Fahimfar N, Azizi F. *A new approach to test validity and clinical usefulness of the 2013 ACC/AHA guideline on statin therapy: A population-based study.* **Int J Cardiol.** 2015 Apr 1;184:587-94.
67. Kazemi H, Ramezani Tehrani F, Minooe S, **Khalili D**, Azizi F. *Women self-perception of excess hair growth, as a predictor of clinical hirsutism: a population-based study.* **J Endocrinol Invest.** 2015 Aug;38(8):923-8.
68. Derakhshan A, Tohidi M, Arshi B, **Khalili D**, Azizi F, Hadaegh F. *Relationship of hyperinsulinaemia, insulin resistance and β -cell dysfunction with incident diabetes and pre-diabetes: the Tehran Lipid and Glucose Study.* **Diabet Med.** 2015 Jan;32(1):24-32.
69. Ayubi E, **Khalili D***, Delpisheh A, Hadaegh F, Azizi F. *Factor analysis of metabolic syndrome components and predicting type 2 diabetes: Results of 10-year follow-up in a Middle Eastern population.* **J Diabetes.** 2015 Nov;7(6):830-8.
70. Jahangiri-Noudeh Y, Akbarpour S, Lotfaliany M, Zafari N, **Khalili D**, Tohidi M, Mansournia MA, Azizi F, Hadaegh F. *Trends in cardiovascular disease risk factors in people with and without diabetes mellitus: a Middle Eastern cohort study.* **PLoS One.** 2014 Dec 2;9(12):e112639.
71. Ramezankhani A, Pournik O, Shahrabi J, Azizi F, Hadaegh F, **Khalili D***. *The Impact of Oversampling with SMOTE on the Performance of 3 Classifiers in Prediction of Type 2 Diabetes.* **Med Decis Making.** 2016 Jan;36(1):137-44.
72. Ramezankhani A, Pournik O, Shahrabi J, **Khalili D**, Azizi F, Hadaegh F. *Applying decision tree for identification of a low risk population for type 2 diabetes. Tehran Lipid and Glucose Study.* **Diabetes Res Clin Pract.** 2014 Sep;105(3):391-8.
73. Farahmand M, Ramezani Tehrani F, Simbar M, Mehrabi Y, **Khalili D**, Azizi F. *Does metabolic syndrome or its components differ in naturally and surgically menopausal women?* **Climacteric.** 2014 Aug;17(4):348-55.
74. Kabir A, **Khalili D**. *Built-in bias in HCV clearance in acute HCV infection.* **J Hepatol.** 2014 Feb;60(2):461.
75. **Khalili D**, Sheikholeslami FH, Bakhtiyari M, Azizi F, Momenan AA, Hadaegh F. *The incidence of coronary heart disease and the population attributable fraction of its risk factors in Tehran: a 10-year population-based cohort study.* **PLoS One.** 2014 Aug 27;9(8):e105804.
76. Derakhshan A, Sardarinia M, **Khalili D**, Momenan AA, Azizi F, Hadaegh F. *Sex specific incidence rates of type 2 diabetes and its risk factors over 9 years of follow-up: Tehran Lipid and Glucose Study.* **PLoS One.** 2014 Jul 16;9(7):e102563.
77. Panahi MH, Yavari P, **Khalili D**, Mehrabi Y, Hadaegh F, Azizi F. *Obesity paradox: coronary heart disease incidence in patients with chronic kidney disease and metabolic syndrome.* **Iranian Journal of Epidemiology.** 2015 Jun 15;11(1):72-81. (Persian Article)
78. Panahi MH, Yavari P, **Khalili D**, Mehrabi Y, Hadaegh F, Azizi F. *The Risk of Chronic Kidney Disease and Metabolic Syndrome in the Incidence of Coronary Heart Disease: Tehran Lipid and Glucose Study.* **Iranian Journal of Epidemiology.** 2014 Mar 15;9(4):10-20. (Persian Article)
79. Tohidi M, Bozorgmanesh M, Mohebi R, **Khalili D**, Saadat N, Khorrani N, Azizi F, Hadaegh F. *Non-*

linear association between 25-hydroxyvitamin D and the incidence of type 2 diabetes: a community-based nested case-control study. **Diabet Med.** 2013 Aug;30(8):934-8.

80. Samadi S, Bozorgmanesh M, **Khalili D**, Momenan A, Sheikholeslami F, Azizi F, Hadaegh F. *Hypertriglyceridemic waist: the point of divergence for prediction of CVD vs. mortality: Tehran Lipid and Glucose Study.* **Int J Cardiol.** 2013 May 10;165(2):260-5.
81. **Khalili D**, Hadaegh F, Steyerberg EW. *The authors reply.* **Am J Epidemiol.** 2013 Apr 15;177(8):865-6.
82. Jahangiri Noudeh Y, Hadaegh F, Vatankhah N, Momenan AA, Saadat N, **Khalili D**, Azizi F. *Wrist circumference as a novel predictor of diabetes and prediabetes: results of cross-sectional and 8.8-year follow-up studies.* **J Clin Endocrinol Metab.** 2013 Feb;98(2):777-84.
83. Hadaegh F, Mohebi R, **Khalili D**, Hasheminia M, Sheikholeslami F, Azizi F. *High normal blood pressure is an independent risk factor for cardiovascular disease among middle-aged but not in elderly populations: 9-year results of a population-based study.* **J Hum Hypertens.** 2013 Jan;27(1):18-23.
84. Mobasheri F, **Khalili D**, Mehrabi Y, Hadaegh F, Movahedi M, Momenan AA, Ghanbarian A, Zayeri F, Azizi F. *Effects of Lifestyle Modification Education on Prevalence of General and Central Obesity in Adults: Tehran Lipid and Glucose Study"* **Journal of Isfahan Medical School.** 2012;30:205. (Persian article)
85. Azimi, S. S., **Khalili D**, Hadaegh F, Mehrabi Y, Yavari P, and Azizi F. *Direct Estimate of Population Attributable Fraction of Risk Factors for Cardiovascular Diseases: Tehran Glucose and Lipid Study.* **Iranian Journal of Epidemiology.** 2012;4:9-18. (Persian article)
86. Mohammadreza B, Farzad H, **Davoud K**, Fereidoun A. *Prognostic significance of the complex "Visceral Adiposity Index" vs. simple anthropometric measures: Tehran lipid and glucose study.* **Cardiovasc Diabetol.** 2012 Mar 7;11:20.
87. **Khalili D**, Hadaegh F, Fahimfar N, Shafiee G, Sheikholeslami F, Ghanbarian A, Azizi F. *Does an electrocardiogram add predictive value to the rose angina questionnaire for future coronary heart disease? 10-year follow-up in a Middle East population.* **J Epidemiol Community Health.** 2012 Dec;66(12):1104-9.
88. Hadaegh F, Jahangiri Noudeh Y, Tohidi M, Vatankhah N, **Khalili D**, Mohebi R, Azizi F. *Change in general and central adiposity measures in prediction of incident dysglycemia; Tehran Lipid and Glucose Study.* **Prev Med.** 2012 Dec;55(6):608-12.
89. Fahimfar N, **Khalili D**, Mohebi R, Azizi F, Hadaegh F. *Risk factors for ischemic stroke; results from 9 years of follow-up in a population based cohort of Iran.* **BMC Neurol.** 2012 Oct 2;12:117.
90. Hatami M, Tohidi M, Mohebi R, **Khalili D**, Azizi F, Hadaegh F. *Adolescent lipoprotein classifications according to National Health and Nutrition Examination Survey (NHANES) vs. National Cholesterol Education Program (NCEP) for predicting abnormal lipid levels in adulthood in a Middle East population.* **Lipids Health Dis.** 2012 Aug 31;11:107.
91. **Khalili D**, Hadaegh F, Soori H, Steyerberg EW, Bozorgmanesh M, Azizi F. *Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran Lipid and Glucose Study.* **Am J Epidemiol.** 2012 Aug 1;176(3):177-86.
92. Hadaegh F, Zabetian A, **Khalili D**, Safarkhani M, Philip T James W, Azizi F. *A new approach to compare the predictive power of metabolic syndrome defined by a joint interim statement versus its*

components for incident cardiovascular disease in Middle East Caucasian residents in Tehran. **J Epidemiol Community Health.** 2012 May;66(5):427-32.

93. Hatami M, Hadaegh F, **Khalili D**, Sheikholeslami F, Azizi F. *Family history of diabetes modifies the effect of blood pressure for incident diabetes in Middle Eastern women: Tehran Lipid and Glucose Study.* **J Hum Hypertens.** 2012 Feb;26(2):84-90.
94. Karami M, **Khalili D**, Eshrati B. *Estimating the proportion of diabetes to the attributable burden of cardiovascular diseases in Iran.* **Iran J Public Health.** 2012;41(8):50-5.
95. Tohidi M, Hasheminia M, Mohebi R, **Khalili D**, Hosseinpanah F, Yazdani B, Nasiri AA, Azizi F, Hadaegh F. *Incidence of chronic kidney disease and its risk factors, results of over 10 year follow up in an Iranian cohort.* **PLoS One.** 2012;7(9):e45304.
96. **Khalili D**, Mosavi-Jarrahi A, Eskandari F, Mousavi-Jarrahi Y, Hadaegh F, Mohagheghi M, Azizi F. *Evaluation of cause of deaths' validity using outcome measures from a prospective, population based cohort study in Tehran, Iran.* **PLoS One.** 2012;7(2):e31427.
97. Hadaegh F, Bozorgmanesh M, Safarkhani M, **Khalili D**, Azizi F. *Predictability of body mass index for diabetes: affected by the presence of metabolic syndrome?.* **BMC Public Health.** 2011 May 25;11:383.
98. Solaymani-Dodaran M, **Khalili D**, Hosseini H, Najafi L, Kamali K, Ranjbar P, Tavakoli H, Ostovar A. *Iranian Registry of Clinical Trials two years on and the timing of registrations.* **J Evid Based Med.** 2011;4(3):168-71.
99. Hadaegh F, Fahimfar N, **Khalili D**, Sheikholeslami F, Azizi F. *New and known type 2 diabetes as coronary heart disease equivalent: results from 7.6 year follow up in a Middle East population.* **Cardiovasc Diabetol.** 2010 Dec 4;9:84.
100. Azizi F, Hadaegh F, **Khalili D**, Esteghamati A, Hosseinpanah F, Delavari A, Larijani B, Mirmiran P, Zabetian A, Mehrabi Y, Kelishadi R, Aghajani H. *Appropriate definition of metabolic syndrome among Iranian adults: report of the Iranian National Committee of Obesity.* **Arch Iran Med.** 2010 Sep;13(5):426-8.
101. Azizi F, **Khalili D**, Aghajani H, Esteghamati A, Hosseinpanah F, Delavari A, Larijani B, Mirmiran P, Mehrabi Y, Kelishadi R, Hadaegh F. *Appropriate waist circumference cut-off points among Iranian adults: the first report of the Iranian National Committee of Obesity.* **Arch Iran Med.** 2010 May;13(3):243-4.
102. Hadaegh F, Zabetian A, Sarbakhsh P, **Khalili D**, James WP, Azizi F. *Appropriate cutoff values of anthropometric variables to predict cardiovascular outcomes: 7.6 years follow-up in an Iranian population.* **Int J Obes (Lond).** 2009 Dec;33(12):1437-45.
103. Hadaegh F, **Khalili D**, Fahimfar N, Tohidi M, Eskandari F, Azizi F. *Glucose intolerance and risk of cardiovascular disease in Iranian men and women: results of the 7.6-year follow-up of the Tehran Lipid and Glucose Study (TLGS).* **J Endocrinol Invest.** 2009 Oct;32(9):724-30.
104. Solaymani-Dodaran M, Ostovar A, **Khalili D**, Vasei M. *Iranian Registry of Clinical Trials: path and challenges from conception to a World Health Organization primary register.* **J Evid Based Med.** 2009 Feb;2(1):32-5.
105. Hadaegh F, **Khalili D**, Ghasemi A, Tohidi M, Sheikholeslami F, Azizi F. *Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in a population of Iranian*

Book Chapters (in Persian)

1. **Khalili D**, Azizi F, Sadeghi-Hasanabadi A. An Introduction to Non-Communicable Diseases. In Azizi F, Janghorbani M, Hatami H. *Epidemiology and Control of Common Diseases in Iran*, Forth edition. Tehran: Khosravi press, 2017
2. Delshad H, **Khalili D**, Azizi F. Diabetes. In Azizi F, Janghorbani M, Hatami H. *Epidemiology and Control of Common Diseases in Iran*, Forth edition. Tehran: Khosravi press, 2017
3. **Khalili D**, Hadaegh F. Hypertension. In Yavari P. *Epidemiology Textbook of Prevalent Diseases in Iran. Volume 2 – Noncommunicable Diseases*. Tehran: Gapnashr, 2014
4. Delshad H, **Khalili D**. Diabetes. In Yavari P. *Epidemiology textbook of Prevalent Diseases in Iran. Volume 2 – Noncommunicable Diseases*. Tehran: Gapnashr, 2014
5. Hosseinpanah F, Barzin M, **Khalili D**. Obesity. In Yavari P. *Epidemiology textbook of Prevalent Diseases in Iran. Volume 2 – Noncommunicable Diseases*. Tehran: Gapnashr, 2014

International Conference Presentations

2018

Cost-Sensitive Measures Vs. Youden`s Index to Determine an Optimal Threshold for Biomarkers: A Practical Approach to Define Pre-Diabetes. *SMDM 17th Biennial European Conference, Leiden, The Netherlands. (Oral)*

2018

Score Risk Function to Predict Cardiovascular Disease Mortality in a Population Outside of Europe: Performance and Challenges. *SMDM 17th Biennial European Conference, Leiden, The Netherlands. (Oral)*

2018

Consistency between Score and Globorisk Prediction Models for Cardiovascular Disease Mortality in a Western Asian Country. *SMDM 17th Biennial European Conference, Leiden, The Netherlands.*

2018

Validation, Calibration, and Clinical Usefulness of FINDRISC, AUSDRISK, ADA Risk Scores for Predicting 5-year Incidence of Diagnosed Type 2 Diabetes in a Middle Eastern Population; the Tehran Lipid and Glucose study. *SMDM 17th Biennial European Conference, Leiden, The Netherlands.*

2016

A Novel Approach to Determine Potential Predictors of Diabetes Among Pre-Diabetic Women: A Population-Based Cohort Study. *17th International Congress of Endocrinology, Beijing, China.*

- 2016
Incorporating Clinical Consequences to Screen for Pre-Diabetes: A Cost-Sensitive Cut-Off for Fasting Plasma Glucose. *17th International Congress of Endocrinology, Beijing, China.*
- 2016
Cardiometabolic Mortality Rate Across Countries Is More Dependent on The Prevalence of Diabetes in Men Than on This Prevalence in Women: An Ecological Study. *17th International Congress of Endocrinology, Beijing, China.*
- 2016
A New Approach to Metabolic Syndrome Components Using Latent Class Analysis (LCA): Dysglycemia Apart From Other Components. *17th International Congress of Endocrinology, Beijing, China.*
- 2016
The Number Needed to Treat for Intensive Statin Therapy in Diabetic Men and Women According to 2013 ACC/AHA Guideline. *17th International Congress of Endocrinology, Beijing, China.*
- 2015
A Systematic Approach to Variable Selection Methods Used In Data-Mining: A Practice in Epidemiology. *European Congress in Epidemiology, Maastricht, The Netherlands. (Oral)*
- 2015
Negative Interaction Between Chronic Kidney Disease and Metabolic Syndrome for Coronary Heart Disease Incidence in Non-Obese Individuals: Risk Factors Paradox. *European Congress in Epidemiology, Maastricht, The Netherlands.*
- 2015
Risk of Coronary Heart Events in Symptomatic and Asymptomatic Individuals: 10 Years Follow-Up in Tehran Lipid and Glucose Study (TLGS). *European Congress in Epidemiology, Maastricht, The Netherland.*
- 2015
Incidence of Recurrent CHD and the Impact of Obesity Paradox in a Population-Based Study: Tehran Lipid and Glucose Study. *European Congress in Epidemiology, Maastricht, The Netherlands.*
- 2015
Application of Net Benefit Fraction to Select Cut-Off for Medical Markers. *European Congress in Epidemiology, Maastricht, The Netherlands.*
- 2014
The Application of Risk Estimation in Guidelines for Statin Therapy. *10th International Congress of Endocrine Disorders, Tehran, Iran. (Oral)*
- 2011
Net Benefit Fraction as a modified Population Attributable Fraction to evaluate the clinical performance of a risk function. *19th World Congress of Epidemiology, Edinburgh, Scotland.*
- 2011
Clinical usefulness of Framingham Cardiovascular Risk Profile during a 10-year follow up in Iran. *19th World Congress of Epidemiology, Edinburgh, Scotland.*

- 2011
An approach to compare the importance of different cardiovascular exposures as continuous variables. *19th World Congress of Epidemiology, Edinburgh, Scotland.*
- 2011
Rose angina vs silent ischemia in prediction of coronary heart disease: Tehran Lipid and Glucose Study. *19th World Congress of Epidemiology, Edinburgh, Scotland.*
- 2011
Different methods to calculate population attributable fraction of risk factors for cardiovascular diseases: Tehran Lipid and Glucose Study (TLGS). *19th World Congress of Epidemiology, Edinburgh, Scotland.*
- 2011
Estimating the attributable burden of cardiovascular disease following reducing the prevalence of diabetes to theoretical and feasible minimum risk level. *19th World Congress of Epidemiology, Edinburgh, Scotland.*
- 2009
Glucose intolerance and risk of cardiovascular disease in Iranian men and women. *the 8th International Congress on Endocrine Disorders, Tehran, Iran. (Oral)*
- 2009
Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in Iranian men population. *3rd International Congress on Prediabetes and the Metabolic Syndrome, Nice, France.*